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A clustering analysis of lipoprotein diameters in
the metabolic syndrome
Alexis C Frazier-Wood1,2*, Stephen Glasser3, W Timothy Garvey4, Edmond K Kabagambe1,5, Ingrid B Borecki6,
Hemant K Tiwari2, Michael Y Tsai7, Paul N Hopkins8, Jose M Ordovas9,10,11 and Donna K Arnett1,5

Abstract
Background: The presence of smaller low-density lipoproteins (LDL) has been associated with atherosclerosis risk,
and the insulin resistance (IR) underlying the metabolic syndrome (MetS). In addition, some research has supported
the association of very low-, low- and high-density lipoprotein (VLDL HDL) particle diameters with components of
the metabolic syndrome (MetS), although this has been the focus of less research. We aimed to explore the
relationship of VLDL, LDL and HDL diameters to MetS and its features, and by clustering individuals by their
diameters of VLDL, LDL and HDL particles, to capture information across all three fractions of lipoprotein into a
unified phenotype.
Methods: We used nuclear magnetic resonance spectroscopy measurements on fasting plasma samples from a
general population sample of 1,036 adults (mean ± SD, 48.8 ± 16.2 y of age). Using latent class analysis, the sample
was grouped by the diameter of their fasting lipoproteins, and mixed effects models tested whether the
distribution of MetS components varied across the groups.
Results: Eight discrete groups were identified. Two groups (N = 251) were enriched with individuals meeting
criteria for the MetS, and were characterized by the smallest LDL/HDL diameters. One of those two groups, one
was additionally distinguished by large VLDL, and had significantly higher blood pressure, fasting glucose,
triglycerides, and waist circumference (WC; P < .001). However, large VLDL, in the absence of small LDL and HDL
particles, did not associate with MetS features. These associations held after additionally controlling for VLDL, LDL
and HDL particle concentrations.
Conclusions: While small LDL diameters remain associated with IR and the MetS, the occurrence of these in
conjunction with a shift to overall larger VLDL diameter may identify those with the highest fasting glucose, TG
and WC within the MetS. If replicated, the association of this phenotype with more severe IR-features indicated
that it may contribute to identifying of those most at risk for incident type II diabetes and cardiometabolic disease.
Keywords: lipoprotein particle diameter, insulin resistance, nuclear resonance spectroscopy, Metabolic Syndrome,
latent class analysis, GOLDN, waist circumference, hypertension, hypertriglyceridemia, fasting glucose

Introduction
IR is defined as cellular resistance to insulin stimulated
glucose uptake. The compensatory hyperinsulinemia
associates with a set of metabolic features that characterize the metabolic syndrome. The National Cholesterol
Education Program (NCEP) Adult Treatment Panel
(ATP) III defined the MetS as the presence of three or
* Correspondence: LekkiWood@Gmail.com
1
Department of Epidemiology, University of Alabama at Birmingham, School
of Public Health, AL, USA
Full list of author information is available at the end of the article

more of the following features: 1) increased WC 2) elevated TGs; 3) low levels of HDL cholesterol (HDL-C);
4) hypertension and, 5) impaired fasting glucose (1).
Given the atherogenic lipid profile seen in the MetS,
and the additional hypertension and central obesity, it is
not surprising that IR has been shown to be a major
risk factor for cardiovascular diseases (CVD) [1,2)].
In addition to the traditional risk factors, an increased
concentration of smaller LDL particles is considered a
biological marker of atherosclerosis risk, IR [3-5] and
the both the presence of the MetS [6,7] and its
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Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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individual components, including raised TG [5,8] and
fasting glucose [4,9], lowered HDL-C [8], increased WC
[10] and hypertension [11]. In addition to the smaller
LDL particles seen in MetS, some preliminary evidence
suggest associations between IR and larger VLDL particles, and between IR and smaller HDL particles
[3,4,12-14]. Despite these associations, how the diameters covary across the three fractions is poorly understood, and, as yet, information on all three fractions of
lipoprotein diameter has not been captured into a single
phenotype and examined for its relationship to disease.
Our first aim was to report how the diameters correlate across VLDL, LDL and HDL particles and confirm
the association between the diameter of each fraction of
lipoprotein and features of the MetS. Our second aim
was to capture the relationship between all three fractions into a single trait, by clustering individuals into
groups according to their similarities across all three
fractions of lipoprotein simultaneously. We further
aimed to examine the distribution of the MetS, and its
individual components across these groupings, and
assess whether any association between group and IR
help when controlling for overall lipoprotein concentrations. This latter step was conducted to ascertain
whether any association between MetS features and
lipoprotein diameter occurs independently of lipoprotein
concentrations, which has been the focus of much previous research.
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Table 1 Means (± standard deviations), or percentages,
for lipoprotein, demographic and MetS characteristics
across the GOLDN study population (N = 1036)
Characteristic

Mean (± standard deviations), or
percentage

Demographics
Male, %

47.8

Age, y

48.8 (16.2)

MetS features
WC; cm

96. 7 (16.8)

Fasting glucose, (mmol/L)

5.63 (1.0)

Diabetes, %
Raised blood pressure (> 130/> 85
mm Hg), %
Systolic blood pressure, mm Hg
Diastolic blood pressure, mm Hg

8.2
29.8
116.1 (16.7)
68.6 (9.7)

Fasting TGs (mmol/L)

1.6 (1.3)

Fasting HDL-C (mmol/L)

1.2 (0.3)

Average no. of MetS counts per
group member

2.2 (1.5)

MetS, %

38.2

Sera lipoprotein particle concentrations (mmol/L)
VLDL

74.1 (49.8)

LDL
HDL

1374.1 (472.7)
31.1 (5.6)

Average particle diameter (nm)
VLDL

51.3 (7.8)

LDL

20.8 (0.9)

HDL

8.8 (0.5)

Results
Group characteristics in lipoproteins, and their
association with components fo the MetS

pattern or significance of the results, and thus, the
results are presented for the full data sample.

Table 1 gives sample characteristics for lipoprotein subfraction distribution. Within the sample as a whole, LDL
diameter was highly correlated with HDL diameter (r =
.78; P < 0.0001), but VLDL diameter was not significantly correlated with LDL diameter (r = -.02; P = 0.51)
nor HDL diameter (r = .02; P = .54).
Table 2 presents the correlations between individual
particle diameters and components of the MetS. LDL
and HDL particle diameters were significantly correlated
with all MetS components (P < .001). VLDL correlated
with MC, fasting glucose and TGs and systolic BP (P <
.001), but did not correlate with HDL-C nor diastolic
BP (P > .05).

Group characteristics in lipoprotein concentrations

Eight groups of lipoprotein diameter clustering

Variable

VLDL

LDL

HDL

LCA identified 8 groups (classes) of individuals. Group
characteristics are reported in table 3. All groups
showed a good internal reliability of a > 0.7. Group 7
consisted of only 7 individuals, while the sample size of
the other groups ranged between 43-242 subjects, so
data from group 7 should be interpreted with caution.
However, analysis without group 7 did not change the

WC

0.14*

-0.41*

-0.43*

Fasting glucose

0.12*

-0.28*

-0.26*

Fasting TGs

0.15*

-0.61*

-0.50*

HDL-C
Systolic BP

-0.01
0.13*

0.69*
-0.22*

0.73*
-0.16*

Diastolic BP

0.05

-0.23*

-0.20

Notably group 6 had the second largest VLDL diameter,
but did not have a high concentration of VLDL particles, indicating that VLDL particle diameter gives information that is not analogous to the absolute
concentration of the VLDL fraction. This was not the
case for the LDL fraction, where the average diameter
decreased as the LDL concentration increased.

Table 2 Pearson correlation coefficients between MetS
features and lipoprotein diameters
Lipoprotein Diameters

*p < 0.001;
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Group characteristics in components of the MetS

LCA group differences were examined using mixed
models that controlled for age and sex, as well as adjusting for between center differences and familial correlation. WC (P < 0.0001, Table 3), fasting blood glucose (P
< 0.0001, Table 3), fasting TG (P < 0.0001, Table 3),
fasting HDL-C concentrations (P < 0.0001, Table 3), the
prevalence of diabetes (P < 0.0001, Table 3) and the percentage of group members with elevated BP (> 130/> 85
mm Hg; P = 0.002, Table 3) all differed significantly
between the 8 groups.
Statistical adjustment for overall lipoprotein concentrations

All group differences remained significant (P < 0.0001)
when models simultaneously controlled for fasting
VLDL, LDL and HDL concentrations; except for fasting
glucose which showed only a trend (P = 0.05; Table 3)
for significance.

Comparisons between groups meeting the NCEP ATP-III
criteria for the MetS

Overall, groups 1 and 2 had the greatest number of
individuals (~75%) that met the ATP-III criteria for the
MetS. Groups 1-2 showed the smallest LDL diameters,
yet the largest VLDL diameters were contained in
groups 2, 6 and 7.
In post hoc analyses, groups 1 and 2 were not significantly different from each other with regard to the number of individuals who met the ATP III criteria for the
MetS (P = 0.80), but WC, TG, glucose and diabetes prevalence were significantly higher (P < 0.001) in LCA
group 2 compared to group 1. Although LDL and HDL
diameter did not differ between groups 1 and 2 (P >
.05), group 2 had significantly larger VLDL diameters (P
< 0.0001) than group 1. As large VLDL diameter alone
did not associate with MetS features, this indicates for

Table 3 Means (± standard deviations), or percentages, for characteristics of each particle diameter group
1

2

3

4

5

6

7

8

N

200

51

242

237

176

43

7

80

a†

.76
(.16; .76-.80)

.80
(.18; .75-.85)

.74
(.18; .72-.76)

.72
(.16; .7-.74)

.74
(.16; .72-.76)

.78
(.17; .73-.83)

.998
(.01; .99-1.00)

.82
(.18; .78-.86)

72

61

Male, %

p-value
*

60

44

28

19

43

14

< 0.0001

Age, y
50.5 (15.0)
50.9 (14.8)
Average particle diameter (nm)

50.6 (15.6)

46.8 (16.7)

47.5 (16.5)

41.1 (17.5)

53.8 (26.1)

49.7 (16.3)

0.001

VLDL

53.1 (3.33)

65.7 (4.9)

45.6 (3.1)

53.6 (3.4)

45.3 (3.0)

64.2 (5.2)

98.1 (14.6)

50.4 (4.1)

< 0.0001

LDL

19.8 (.4)

20.1 (.6)

20.4 (.4)

21.1 (.4)

21.5 (.4)

21.7 (.6)

21.9 (.6)

22.2 (.4)

< 0.0001

HDL

8.4 (.2)

8.5 (.2)

8.6 (.2)

9.0 (.2)

9.2 (.2)

9.4 (.3)

9.7 (.3)

9.7 (.3)

< 0.0001

Distributions of lipoprotein subfractions (sera concentrations; nmol/L)
VLDL
Small

39.5 (25.6)

26.2 (17.3)

43.5 (23.8)

27.6 (14.3)

32.6 (18.2)

11.1 (8.7)

4.6 (7.0)

18.6 (14.2)

< 0.0001

Medium
Large

61.2 (37.5)
7.88 (5.5)

45.6 (51.3)
17.8 (24.6)

44.4 (33.7)
1.8 (1.9)

27.8 (34.0)
3.8 (5.3)

28.1 (24.4)
.8 (1.0)

8.9 (7.3)
1.4 (2.3)

3.0 (2.3)
.4 (0.4)

17.7 (14.8)
.9 (1.3)

< 0.0001
< 0.0001

Very small

1208.4
(400.9)

1005.9
(359.3)

886.2 (374.8)

546.5 (266.4)

364.7 (227.4)

298.9 (273.0)

274.1 (219.1)

171.0 (156.8)

< 0.0001

Small

1516.6
(462.2)

1313.9
(466.4)

1178.7
(410.5)

745.2 (289.2)

528.1 (256.7)

431.0 (333.6)

351.0 (270.5)

215.4 (190.0)

< 0.0001

Medium
small

308.2 (123.4)

308.1 (219.5)

292.5 (212.1)

198.6 (176.6)

163.4 (190.9)

132.1 (174.0)

76.89 (55.88)

44.7 (38.15)

< 0.0001

Large

154.6 (116.1)

238.5 (215.7)

291.3 (146.7)

470.8 (189.7)

560.7 (228.3)

630.1 (192.4)

775.99 (271.34)

746.86
(245.26)

< 0.0001

Small

25.0 (5.0)

24.6 (5.4)

23.7 (4.9)

20.6 (4.7)

19.9 (5.1)

16.4 (4.9)

16.58 (4.74)

17.89 (4.51)

< 0.0001

Medium

1.5 (2.7)

2.7 (3.3)

1.9 (2.5)

4.3 (3.9)

4.0 (4.2)

5.8 (4.2)

3.22 (5.22)

2.43 (3.02)

< 0.0001

Large

3.0 (1.7)

3.3 (1.9)

4.6 (1.8)

6.9 (2.4)

8.7 (2.3)

10.0 (2.5)

11.50 (3.41)

12.42 (2.44)

< 0.0001

LDL

HDL

Sera lipoprotein particle concentrations (nmol/L)
VLDL

108.6 (51.4)

76.4 (54.2)

80.4 (39.1)

58.5 (38.7)

61.2 (29.8)

28.8 (12.6)

11.60 (5.21)

42.19 (20.69)

< 0.0001

LDL

1760.0
(469.2)

1624.3
(488.8)

1520.8
(424.6)

1202.6
(353.6)

1086.4
(330.6)

1025.0
(338.5)

1050.72
(205.79)

969.10
(304.47)

< 0.0001

HDL

29.1 (5.5)

30.2 (5.3)

29.4 (5.7)

31.0 (5.5)

31.7 (5.1)

31.8 (5.5)

31.89 (6.44)

32.01 (5.19)

< 0.0001

*Controls for family structure; Values in the table are means+/-SD, etc.
† a is the internal reliability of the class and values above 0.70 are considered reliable [18].
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the first time that it is the pattern of VLDL to LDL or
HDL diameter that is indicative of MetS feature severity.

Discussion
The aim of this study was examine how the diameters of
three fractions of lipoprotein co-varied, and to create a
phenotype that, for the first time, reflects the pattern of
lipoprotein diameters across VLDL, LDL and HDL particles. By examining the co-variation of this phenotype
with the individual components of the MetS, we report
that the MetS occurs alongside a reduction in LDL and
HDL particle diameters. However, although VLDL diameter alone does not associate with MetS features,
some of the most extreme IR features (the highest glucose, diabetes prevalence, TG, and WC) occur alongside
smaller LDL and HDL particles, simultaneously with larger VLDL particles. As increased fasting glucose and
TGs and increased WC are important indicators of
CVD risk, the pattern of VLDL-LDL (or VLDL-HDL)
diameters may have implications for starting identifying
the highest risk groups for progression of IR into type II
diabetes and cardiovascular disease.
Although previous studies into the role of LDL particle size in the MetS have largely used an increase in the
concentration of the small LDL subfraction(s) as a marker of the MetS, previous analyses using particle diameters have been shown to be analogous to results
using the concentration of particle subfractions [4].
Using diameters as trait components, instead of subfraction concentrations, has two potential advantages: [1]
there is no clear agreement on the number of subfractions within each fraction. Diameters are measured in
nm and are a standardized unit. Using a standardized
measurement (such NMR-based nm scale) over subfractions based on centrifugation and related techniques,
makes replication in independent samples more straightforward, and may ease the use of information in clinical
settings. The average diameter may reflect the distribution across NMR-based subfractions more than a single
subfraction concentration alone. That is, an increase in
a particular subfraction concentrations does not give
information about whether this reflects an overall
increase across all the subfractions. Overall shift in average particle diameter reflects subfraction distribution.
Our descriptive analysis reports that the MetS, and its
individual features were characterized by small LDL and
HDL particles. Previous research suggests that an
increased concentration of small LDL particles is considered a marker of raised TG [5,8], raised fasting glucose [4,9], lowered HDL-C [8], increased WC [10] and
hypertension [11]. Much of the research supports a shift
to smaller HDL in IR [3,4,12-14]. The groups created
during the LCA showed significant differences in all
components of the MetS, and so our study unifies
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previous information, and supports the association of
small LDL [7] and HDL particles with the components
of the MetS.
To extend our understanding of how lipoprotein diameters may be a marker of IR features, LCA analysis
grouped individuals by their similarities for each of the
three fractions of lipoprotein. Thus, the groups reflected
relationships between the diameters of the various fractions of lipoprotein within a unified trait. As LDL particle diameter increased across the groups, so did HDL
particle diameter. VLDL diameter was not correlated
with LDL diameter, which is important as it indicates at
least partially separable genetic and/or environmental
influences to LDL and VLDL particle diameter
formation.
The groups containing individuals with small LDL and
HDL diameters are highly enriched for the presence of
the MetS, a risk factor for incident diabetes and cardiometabolic disease [1,2]. The inclusion of VLDL diameter
into the particle diameter pattern stratified those with
the MetS into two further groups, one of which (group
2) has more extreme IR features i.e., increased WC, glucose, TG and diabetes prevalence, although there was
not a significant difference in the average number of
MetS components between the groups. Thus, when LDL
diameter is known, the inclusion of HDL diameter in a
trait is minimally informative. But knowledge of the
VLDL diameter increased trait sensitivity as to the
degree of abnormality across several of the individual
components of the MetS. Given the relationship of IR to
and cardiovascular events [2], this trait may provide, or
contribute to, a useful tool, available from a quick
serum test, for identifying those at the highest risk of
incident diabetes or cardiometabolic disease from those
who meet MetS criteria.
To confirm that the associations between the groups
and components of the MetS were not confounded by
an association between particle diameter and overall
particle numbers, we additionally controlled for lipoprotein concentrations. In these models, WC, fasting
TG, systolic BP and HDL-C did differ significantly
between the groups (P < 0.0001), but fasting glucose
and diastolic BP showed only a trend towards an association (P = 0.05). Thus, the association between the
mean value for components of the MetS and a trait
created from fasting particle diameter pattern is not
attributable to any shared association with overall lipoprotein concentrations.
Although the clustering of individuals by VLDL, LDL
and HDL particle diameter may provide an important
trait for future risk stratification, our study should be
viewed in light of some limitations. Firstly, differences
by race both in lipoprotein patterns, and in the association of lipoprotein pattern with MetS features needs
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examination, which was not possible within the current
sample. Secondly, and crucially, the use of cross-sectional data precluded any causal inferences regarding
predictive value of particle diameter clustering to the
MetS, or regarding the association between particle diameter clustering and incident diabetes/cardiometabolic
disorder. This is an important future direction for this
work.
Overall, while LDL particle diameter correlated with
HDL particle diameter (in a fasted state), VLDL diameter varied independently of LDL, and the inclusion of
information on diameter from three fractions of lipoprotein was more informative about MetS features than
that of a single fraction. The MetS was marked by small
LDL and HDL diameters, but, together, large VLDL and
small LDL and HDL diameters marked those with the
highest glucose, diabetes prevalence, TG, and WC.
Thus, together, a combination of LDL and VLDL diameter may provide the best tool for identifying those at
increased risk for type II diabetes or CVD. It is of great
interest to see, in longitudinal studies, if changes in lipoprotein diameter pattern occur before the presence of
the MetS, or simply alongside, and to establish whether
this pattern of small LDL and large VLDL particles can
be shown to convey increased risk for incident diabetes
and cardiovascular events.

Material and methods
Participants

The study population consisted of 1,328 men and
women in the Genetics of Lipid-Lowering Drugs and
Diet Network (GOLDN) study. All participants were
white men and women recruited from Minneapolis,
Minnesota and Salt Lake City, Utah. The primary aim of
the GOLDN study was to characterize the role of
genetic and dietary factors on an individual’s response
to fenofibrate; and, the details of the GOLDN study
have been published elsewhere [15]. GOLDN consisted
of an initial screening visit (visit 0) during which participants were asked to discontinue the use of lipid lowering drugs. Approximately 4 to 8 weeks later, baseline
blood chemistries were measured (visit 1). A day later
(visit 2) participants’ blood samples were collected
before (fasting) and after (postprandial) participating in
a high fat meal challenge. On subsequent visits 3 and 4,
fasting and postprandial blood samples were collected
after a 3-week open label fenofibrate trial. For this analysis, we used fasting data from visit 2. This includes
data only from subjects who were willing to participate
in the high fat meal intervention. The final sample consisted of 1036 individuals across 187 families; 497 men
and 539 women (mean ± SD: 48.8 ± 16.2 y of age). The
protocol was approved by the Institutional Review
Boards at the University of Minnesota, University of
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Utah, Tufts University/New England Medical Center
and the University of Alabama at Birmingham. Written
informed consent was obtained from all participants.
Data collection

Clinical characteristics including anthropometric and
blood-pressure measurements were taken at the study
clinics where a fasting blood sample was also drawn, as
described previously [15]. Questionnaires were administered to collect demographic data and information on
lifestyle attributes and medical history.
Anthropometric data

WC and BP data were collected by trained research staff
who were instructed to take measurements against the
skin or over lightweight non-constricting underwear.
The tape was placed horizontally at the level of the
umbilicus (navel), and the results recorded to the nearest centimeter, rounded down. BP data for both systolic
and diastolic measurement were taken as the average of
two consecutive readings which was rounded to the
nearest integer.
Biochemical measurements

All plasma samples used for this analysis were collected
after an 8-hour fast and analyzed together at the end of
the study. Measurements of overall plasma TG, VLDL,
LDL, HDL and HDL-C concentrations were determined
using enzymatic assays as previously described [16]. The
serum concentrations of each subfraction are expressed
in nmol/L. Measurements of VLDL, LDL and HDL diameter, and concentrations of each subfraction were
determined by nuclear magnetic resonance (NMR) spectroscopy [17]. NMR detects the signal emitted by lipoprotein methyl-group protons when in the field of a
magnet charged at 400 MHz. The NMR signal is deconvoluted to obtain estimates of particle numbers for each
of several lipoprotein fractions. The weighted average
particle diameter for each lipoprotein fraction (VLDL,
LDL and HDL) is calculated as the sum of the average
lipoprotein particle diameters multiplied by the relative
mass percentage, based on the amplitude of the methyl
NMR signal and given in nm. The ranges of diameters
within each subfraction are shown in Table 4. Note that
NMR groups IDL as a subclass of LDL [17].
MetS components

The NCEP ATP III definition is used in this analysis,
defined as the presence of three or more of the following features: 1) WC > 102 cm [> 40 in] for men, > 88
cm [> 35 in] for women; 2) TG ≥ 150 mg/dl; 3) HDL-C;
< 40 mg/dl in men, < 50 mg/dl in women; 4) blood
pressure (BP) ≥ 130 ≥ 85 mmHg; and 5) impaired fasting glucose = > 100 mg/dl [1].
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Table 4 Diameter ranges of lipoprotein subclasses when
measured by NMR [17]
NMR lipoprotein parameter

Diameter range (nm)

VLDL
Large VLDL/chylomicrons

> 60

Medium VLDL
Small VLDL

35-60
27-35

LDL
IDL

23-27

Large LDL
Small LDL
Medium small LDL
Very small LDL

21.2-23
18-21.2
19.8-21.2
18-19.8

HDL
Large HDL

8.8-13

Medium HDL

8.2-8.8

Small HDL

7.3-8.2

Statistical analysis

Statistical analyses were carried out using SAS for Windows, version 9.2 (SAS Institute, Cary, NC).
Initial analysis

Pearson correlations were run to examine the correlation
between components of the MetS and lipoprotein diameters. For this analysis, TG concentrations and VLDL
diameter were skewed and a natural logarithmic transformation applied to approximate a normal distribution.
Clustering of individuals, into groups, based on similar
VLDL, LDL and HDL diameters

Latent class analysis (LCA), a form of cluster analysis
that groups individuals based on similarities within specified measures, was used to group study participants
into 8 groups based on their average VLDL, LDL and
HDL fractions. The aim of these analyses was to cluster
together individuals who have a similar absolute average
diameter for each of the three fractions of lipoprotein
(VLDL, LDL and HDL).
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Advantages of LCA

Unlike commonly used difference methods, such as raw
or residual difference scores, LCA can characterize
means and differences across more than two measures.
Further, LCA allows for a multinomial pattern of difference. Where responses can increase or decrease (e.g.
LDL may be larger or smaller than VLDL), alternative
methods can (1) oversimplify and (2) average out these
complex difference patterns. LCA also allows a statistically significant assessment, through maximum-likelihood model fit comparisons, of the number of discrete
groups within a population.
The LCA was implemented using the TRAJ Procedure in SAS [18]. LCA clusters individuals into classes
according to similarities in the mean diameter for each
fraction of lipoprotein using an iterative approach [19].
Initially, all participants are considered to be in a single class. Classes are added until an additional class
does not improve the fit of the model as assessed
using the log Bayes Factor (logBF). LCA uses maximum
likelihood estimation, with standardized data to ease
optimization.
For each individual, the probability of membership of
each group is given (which all sum to 1.00). Using a
maximum-probability assignment rule, each individual is
assigned to the group for which he/she has the highest
probability of membership. The average posterior probability of group membership is the average of all the
membership probabilities of all participants assigned to
that group and is analogous to the internal reliability
(the a) of the class. An average posterior probability of
over 0.70 is considered reliable [19]. Figure 1 represents
the results of the LCA, using standardized data for ease
of display. For this figure only, each fraction of lipoprotein was standardized using the PROC STANDARD
command.
Group characteristics

We used mixed models to determine whether the distribution of lipid particle subfraction concentrations and
components of the MetS varied significantly by LCA

Figure 1 Relative VLDL, LDL and HDL diameters by group. Note: For display, the data are standardized within each fraction.

Frazier-Wood et al. Lipids in Health and Disease 2011, 10:237
http://www.lipidworld.com/content/10/1/237

groups. In these models, study center and pedigree were
modeled as random effects.
Categorical MetS variables were modeled using PROC
GENMOD while continuous ones were modeled using
PROC MIXED in models that included LCA group, sex
and age as fixed effects. The categorical MetS variables
were hypertension and diabetes prevalence, while the continuous ones were WC, fasting glucose, TG and HDL-C
concentrations. Systolic and diastolic measurements were
included as continuous variables, for additional information.
Additional models were then run which controlled for
VLDL, LDL and HDL concentrations.
Sensitivity analysis

To exclude the possibility that any significant betweengroup differences in components of the MetS were driven by a few extreme data points or outliers, all mixed
models were additionally run without values +/- 4 SD
from the mean of the outcome variable. The direction
of results, and all significance levels remained the same,
so results are reported here using the full sample.
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